Video

Dr. Poveda on the Results of the SOLO2 Trial in Ovarian Cancer

Andres Poveda, MD, discusses the results of the phase 3 SOLO2 trial in advanced ovarian cancer.

Andres Poveda, MD, Initia Oncology, Hospital Quironsalud, in Valencia, Spain, discusses the results of the phase 3 SOLO2 trial in advanced ovarian cancer.

The results of the SOLO2 trial support the use of PARP inhibitors as maintenance therapy in patients with advanced platinum-sensitive relapsed ovarian cancer who harbor BRCA1/2 mutations, says Poveda. In the trial, olaparib (Lynparza) led to a clinically meaningful improvement in overall survival (OS) versus placebo in this patient population.

The median OS was 51.7 months with the PARP inhibitor versus 38.8 months with placebo (HR, 0.74; 95% CI, 0.54-1.00; P = .0537). At 5 years, 42.1% of women who received olaparib were alive versus 33.2% of those who received placebo. The SOLO2 trial is the first phase 3 trial to provide OS data on a maintenance PARP inhibitor, says Poveda.

Additionally, 22% of patients received olaparib for at least 5 years, reflecting the clinical benefit and tolerability of the agent.

<<< 2020 ASCO Virtual Scientific Program

Related Videos
Jerôme Fayette, MD, PhD, medical oncologist, Centre Léon Bérard
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Rebecca Klisovic, MD
Kedar Kirtane, MD, assistant member, Department of Head and Neck-Endocrine Oncology; medical director, Solid Tumor Cellular Therapy, Moffitt Cancer Center
Rohan Garje, MD
Cynthia Ma, MD, PhD
Arya Mariam Roy, MBBS
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Marc-Oliver Grimm, MD